Continuous Renal Replacement Therapy
Conditions
Interventions
The test groups:Phosphrate Hemofiltration Replacement Solution
The control group:Hemofiltration basic solution
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study. 1) Age 18-70 years old (including 18 years old and 70 years old), gender is not limited; 2) Meet the CRRT indications in the Standard Operating Procedures for Blood Purification (2021 Edition) and have been assessed by a qualified nephrology or critical care physician to require CRRT treatment; 3) Planned continuous blood purification time= 48 hours; 4) Patients or their guardians have a full understanding of the purpose and significance of this trial, voluntarily participate in this study and follow the study procedures, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: Subjects who meet any of the following criteria will not be allowed to participate in this study. 1) Those who are known to be allergic to any component of the test drug, or those who are allergic; 2) inability to establish suitable vascular access; 3) with refractory hypotension (systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg); 4) Have malignant tumors with or without systemic metastases; 5) Combined with thromboembolic disease; 6) Pregnant and lactating females; 7) Patients who have received CRRT treatment within 72 hours before screening; 8) Those who have used other experimental drugs or devices within 1 month before screening, or participated in other clinical trials at the same time; 9) Patients who, in the opinion of the investigator, are not suitable to participate in this study due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hypophosphatemia within 48 hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of hypophosphatemia within 24 hours;Frequency of hypophosphatemia within 24 hours and 48 hours;Frequency and amount of phosphorus supplementation;Incidence of hyperglycemia;Insulin usage;Degree of change from baseline in serum creatinine;Sequential Organ Failure Score (SOFA); | — |
Countries
China
Contacts
Public ContactLing.Zhang / Ping.Feng
West China Hospital of Sichuan University
Outcome results
None listed